Charles River Laboratories International, Inc. (CRL) — Analyst outlook / Analyst consensus target is. Based on 36 analyst ratings, the consensus is bullish — 1 Strong Buy, 24 Buy, 11 Hold.
The consensus price target is $202.17 (low: $175.00, high: $260.00), representing an upside of 12.7% from the current price $179.31.
Analysts estimate Earnings Per Share (EPS) of $10.18 and revenue of $4.03B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $0.20 vs est $10.18 (missed -98%). 2025: actual $-2.91 vs est $10.24 (missed -128.4%). Analyst accuracy: 0%.
CRL Stock — 12-Month Price Forecast
$202.17
▲ +12.75% Upside
Average Price Target
Based on 36 Wall Street analysts offering 12-month price targets for Charles River Laboratories International, Inc., the average price target is $202.17, with a high forecast of $260.00, and a low forecast of $175.00.
The average price target represents a +12.75% change from the last price of $179.31.
Highest Price Target
$260.00
Average Price Target
$202.17
Lowest Price Target
$175.00
CRL Analyst Ratings
Buy
Based on 36 analysts giving stock ratings to Charles River Laboratories International, Inc. in the past 3 months
EPS Estimates — CRL
0%
Analyst Accuracy
Inaccurate
2 years compared
Actual vs Estimate
2024
Actual $0.20
vs Est $10.18
▼ 4,991.6% off
2025
Actual –$2.91
vs Est $10.24
▼ 451.9% off
Profitability Outlook
Company has mixed profitability — some years profitable, some at a loss. Analysts expect the company to turn profitable.
Revenue Estimates — CRL
100%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual $4.050B
vs Est $4.030B
▲ 0.5% off
2025
Actual $4.015B
vs Est $4.005B
▲ 0.3% off
Revenue Trend
Revenue has been relatively flat. Analysts expect stable revenue going forward.
